IDEX Corporation (NYSE: IEX) today announced its financial results for the three-month period ended September 30, 2012. New orders in the quarter totaled $464 million, down 3 percent from the prior year period. Sales in the quarter totaled $480 million, 1 percent higher than the prior year period. For the quarter, on an organic basis, orders were 4 percent lower and sales were 1 percent higher than the prior year period. Third quarter 2012 operating income, adjusted for $7.1 million of restructuring related charges, was $87.7 million, resulting in an adjusted operating margin of 18.3 percent, equal to the prior year adjusted operating margin. Excluding the impact of restructuring related charges in both years and the acquisition fair value inventory charge in the prior year, third quarter adjusted earnings per share were 66 cents, a decrease of 5 cents, or 7 percent. The unfavorable year-over-year variance is primarily the result of two one-off items – a prior year benefit from CEO forfeited equity compensation and a true-up of the 2011 year-to-date tax rate. Free cash flow was $92 million for the quarter, a 7 percent increase from the third quarter of the prior year due to higher operating income and improved working capital. Additionally, the Company’s Board of Directors has increased the authorized level for repurchases of common stock by $200 million. The increased authorization will be added to the approximately $50 million that remains available from the existing authorization approved by the Board of Directors in December 2011. Repurchases under the program will be funded with future cash flow generation. Third Quarter Highlights
- Orders decreased 3 percent compared to the prior year (-4 percent organic, +3 percent acquisition and -2 percent foreign currency translation).
- Sales increased 1 percent compared to the prior year (+1 percent organic, +2 percent acquisition and -2 percent foreign currency translation).
- Reported net income of $50 million was $2 million, or 4 percent, higher than the prior year. Excluding restructuring related charges, adjusted net income was $55 million or 7 percent lower than prior year adjusted net income.
- Reported EPS of 60 cents was 2 cents, or 3 percent, higher than the prior year EPS. Adjusted EPS of 66 cents was 5 cents, or 7 percent, lower than the prior year adjusted EPS.
- EBITDA of $100 million was 21 percent of sales and covered interest expense by nearly 10 times.
- Free cash flow was $92 million, representing a record and over 180 percent of net income. Year-to-date free cash flow continues to be strong – up 41 percent from the prior year.
- During the quarter, the Company completed another strategic acquisition, Matcon, a global leader in material processing solutions in the Pharmaceuticals, Food, Plastics and Fine Chemicals industries.
- The Company completed the repurchase of 1 million shares of common stock for $39 million in the third quarter. Over two percent of the outstanding shares of common stock, or 1.9 million shares, have been purchased by the Company in 2012.
Our strong balance sheet and cash generation provide us ample opportunity to deploy capital and remain focused on delivering robust and consistent shareholder returns. In addition to our longstanding investment priorities of organic growth and strategic acquisitions, our Board of Directors has increased the authorization level for the repurchase of our shares by $200 million, providing us with approximately $250 million of total availability. Annually, we intend to repurchase a minimum of one to two percent of the Company’s outstanding shares of common stock, with the flexibility to opportunistically increase the purchases when the stock is trading at a discount to the Company’s intrinsic value. We believe the repurchase of our shares in conjunction with consistent shareholder dividends and strategic acquisitions is a prudent use of our cash flow to maximize our shareholders’ total return.We expect market conditions to remain challenging, specifically outside the US, resulting in expected fourth quarter flat organic revenue. Despite this market volatility, our disciplined execution allows us to maintain our prior full year 2012 adjusted EPS guidance of $2.65 - $2.70.” Andrew K. SilvernailChairman and Chief Executive Officer Third Quarter 2012 Business Highlights (Operating margin excludes restructuring related and non-cash fair value inventory charges) Fluid & Metering Technologies
- Sales in the third quarter of $198 million reflected a 4 percent decrease compared to the third quarter of 2011 (-1 percent organic and -3 percent foreign currency translation).
- Operating margin of 21.4 percent represented a 130 basis point improvement compared with the third quarter of 2011 primarily due to productivity and cost reduction initiatives.
- Sales in the third quarter of $176 million reflected a 2 percent increase compared to the third quarter of 2011 (-4 percent organic, +7 percent acquisitions and -1 percent foreign currency translation).
- Operating margin of 17.3 percent represented a 150 basis point decrease compared with the third quarter 2011 primarily due to lower margins from recently acquired businesses.
- Sales in the third quarter of $108 million reflected a 10 percent increase compared to the third quarter of 2011 (+13 percent organic and -3 percent foreign currency translation).
- Operating margin of 24.8 percent represented a 360 basis point increase compared with the third quarter of 2011 primarily due to improved productivity and cost reduction initiatives.
EBITDA and Free Cash FlowEBITDA means earnings before interest, income taxes, depreciation and amortization, while free cash flow means cash flow from operating activities less capital expenditures plus the excess tax benefit from stock-based compensation. Management uses these non-GAAP financial measures as internal operating metrics and for enterprise valuation purposes. Management believes these measures are useful as analytical indicators of leverage capacity and debt servicing ability, and uses them to measure financial performance as well as for planning purposes. However, they should not be considered as alternatives to net income, cash flow from operating activities or any other items calculated in accordance with U.S. GAAP, or as an indicator of operating performance. The definitions of EBITDA and free cash flow used here may differ from those used by other companies.
|EBITDA and Free Cash Flow Bridge||For the Quarter Ended|
|September 30,||June 30,|
|Income before taxes||$70.2||$63.1||11||%||$77.9||(10)||%|
|Depreciation and amortization||19.5||20.5||(5)||19.2||2|
|CVI fair value inventory charge||-||12.8||(100)||-||-|
|Cash Flow from operating activities||$101.0||$94.8||7||%||$80.7||25||%|
|Excess tax benefit from stock-based compensation||0.8||0.9||(8)||0.3||n/m|
|Free cash flow||$92.4||$86.3||7||$70.8||30|
About IDEXIDEX Corporation is an applied solutions company specializing in fluid and metering technologies, health and science technologies, and fire, safety and other diversified products built to its customers’ exacting specifications. Its products are sold in niche markets to a wide range of industries throughout the world. IDEX shares are traded on the New York Stock Exchange and Chicago Stock Exchange under the symbol “IEX”. For further information on IDEX Corporation and its business units, visit the company’s website at www.idexcorp.com . (Tables follow)
|Condensed Statements of Consolidated Operations|
|(in thousands except per share amounts)|
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Cost of sales||285,019||295,349||862,578||812,697|
|Selling, general and administrative expenses||107,167||107,296||332,431||313,485|
|Other expense (income) - net||(132||)||441||(19||)||1,001|
|Income before income taxes||70,184||63,101||222,092||206,717|
|Provision for income taxes||20,057||14,765||65,443||60,248|
|Earnings per Common Share:|
|Basic earnings per common share (a)||$||0.60||$||0.58||$||1.88||$||1.77|
|Diluted earnings per common share (a)||$||0.60||$||0.58||$||1.87||$||1.75|
|Basic weighted average common shares outstanding||82,482||82,402||82,820||81,994|
|Diluted weighted average common shares outstanding||83,370||83,586||83,785||83,533|
|Condensed Consolidated Balance Sheets|
|September 30,||December 31,|
|Cash and cash equivalents||$||260,503||$||230,259|
|Receivables - net||277,505||252,845|
|Other current assets||56,292||51,799|
|Total current assets||843,864||789,161|
|Property, plant and equipment - net||223,762||213,717|
|Goodwill and intangible assets||1,869,481||1,813,588|
|Other noncurrent assets||20,328||19,641|
|Liabilities and shareholders' equity|
|Trade accounts payable||$||117,793||$||110,977|
|Total current liabilities||294,042||258,278|
|Other noncurrent liabilities||271,788||258,328|
|Total liabilities and shareholders' equity||$||2,957,435||$||2,836,107|
|Company and Business Group Financial Information|
|(dollars in thousands)|
|Three Months Ended||Nine Months Ended|
|September 30, (b)||September 30, (b)|
|2012||2011 (c)||2012||2011 (c)|
|Fluid & Metering Technologies|
|Net sales||$ 198,000||$ 205,797||$ 621,433||$ 614,367|
|Operating income (d)||42,368||41,462||136,175||124,800|
|Depreciation and amortization||$ 7,246||$ 8,603||$ 22,194||$ 24,841|
|Health & Science Technologies|
|Net sales||$ 176,225||$ 172,911||$ 520,574||$ 442,619|
|Operating income (d) (e)||30,480||32,515||90,494||91,881|
|Depreciation and amortization||$ 10,273||$ 9,712||$ 29,293||$ 20,686|
|Fire & Safety/Diversified Products (c)|
|Net sales||$ 108,199||$ 98,735||$ 328,173||$ 302,814|
|Operating income (d)||26,807||20,965||78,165||68,972|
|Depreciation and amortization||$ 1,622||$ 1,844||$ 5,225||$ 6,561|
|Net sales||$ 479,859||$ 476,881||$ 1,463,420||$ 1,357,768|
|Operating income (d)||87,673||87,036||268,411||247,386|
|Depreciation and amortization (f)||$ 19,545||$ 20,540||$ 57,938||$ 53,116|
|(a)||Calculated by applying the two-class method of allocating earnings to common stock and participating securities as required by ASC 260, Earnings Per Share.|
|(b)||Three and nine month data includes acquisitions of Matcon (July 2012), ERC (April 2012), CVI Melles Griot (June 2011), Microfluidics (March 2011) and Advanced Thin Films (January 2011) in the Health & Science Technologies segment from the date of acquisition.|
|(c)||Financial data for 2011 has been revised to reflect the transfer of our Trebor business unit from the Health & Science Technologies segment to the Fluid & Metering Technologies segment as well as the movement of the Dispensing Equipment segment into the Fire & Safety/Diversified Products segment.|
|(d)||Group operating income excludes unallocated corporate operating expenses while both Group and Company operating income excludes restructuring related charges.|
|(e)||Operating income excludes $12.8 million and $15.8 million for the three and nine months ending September 30, 2011, respectively, related to a non-cash acquisition fair value inventory charge.|
|(f)||Depreciation and amortization excludes amortization of debt issuance expenses.|